Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Accumulated Expenses (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Accumulated Expenses data on record, last reported at $17.1 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 56.42% year-over-year to $17.1 million; the TTM value through Sep 2025 reached $17.1 million, up 56.42%, while the annual FY2024 figure was $8.2 million, 65.21% down from the prior year.
  • Accumulated Expenses reached $17.1 million in Q3 2025 per SGMO's latest filing, up from $15.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $23.6 million in Q4 2023 and bottomed at $5.7 million in Q2 2024.
  • Average Accumulated Expenses over 5 years is $14.7 million, with a median of $14.2 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: crashed 70.18% in 2024, then surged 172.77% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $11.6 million in 2021, then soared by 85.76% to $21.5 million in 2022, then increased by 9.52% to $23.6 million in 2023, then tumbled by 65.21% to $8.2 million in 2024, then soared by 109.21% to $17.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $17.1 million in Q3 2025, $15.4 million in Q2 2025, and $9.8 million in Q1 2025.